DBIA
ORMP icon

Dumont & Blake Investment Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Dumont & Blake Investment Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,800
Closed -$69K – 222
2021
Q4 		$69K Buy
+4,800
New +$100K 0.02% 199

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Dumont & Blake Investment Advisors's ORMP Position: Q1 2022 in Review

Dumont & Blake Investment Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q1 2022, closing a stake of 8,250 shares — an estimated $118K sold.

Dumont & Blake Investment Advisors first reported a position in ORMP in Q3 2021 and held it in 2 quarters. The position peaked at $177K in Q3 2021. 103 funds tracked by Wall St. Rank hold ORMP as of Q1 2022.

  • Dumont & Blake Investment Advisors reported no remaining Oramed Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Dumont & Blake Investment Advisors sold 8,250 Oramed Pharmaceuticals shares in Q1 2022, an estimated $118K.
  • Dumont & Blake Investment Advisors first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Dumont & Blake Investment Advisors's Oramed Pharmaceuticals position peaked at $177K in Q3 2021.
  • 103 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2022.

Based on Dumont & Blake Investment Advisors's 13F filing for Q1 2022, filed 27 Apr 2022.